Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection.

Rao GK, Prell RA, Laing ST, Burleson SCM, Nguyen A, McBride JM, Zhang C, Sheinson D, Halpern WG.

Toxicol Sci. 2019 Jun 1;169(2):409-421. doi: 10.1093/toxsci/kfz053.

PMID:
30796434
2.

Resolution of unexpected pregnancy-related findings in a rat embryofetal development and toxicokinetic study of monoclonal antibodies specific for hCMV.

Katavolos P, Prell R, Zane D, Deng R, Halpern W.

Birth Defects Res. 2018 Nov 1;110(18):1347-1357. doi: 10.1002/bdr2.1402. Epub 2018 Oct 31.

PMID:
30381912
3.

Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3.

Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, Clark R, Johnston J, Shelton A, Mai E, Gadkar K, Lo AA, Koerber JT, Totpal K, Prell R, Lee G, Spiess C, Junttila TT.

Sci Transl Med. 2018 Oct 17;10(463). pii: eaat5775. doi: 10.1126/scitranslmed.aat5775.

PMID:
30333240
4.

Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys.

Prell RA, Dybdal N, Arima A, Chihaya Y, Nijem I, Halpern W.

Toxicol Sci. 2018 Sep 1;165(1):186-197. doi: 10.1093/toxsci/kfy141.

PMID:
29893934
5.

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.

Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, Wong A, Tam L, Newman R, Vuillemenot BR, Ellerman D, Gu C, Mathieu M, Dennis MS, Nguyen A, Zheng B, Zhang C, Lee G, Chu YW, Prell RA, Lin K, Laing ST, Polson AG.

Blood. 2017 Feb 2;129(5):609-618. doi: 10.1182/blood-2016-08-735365. Epub 2016 Dec 1.

6.

Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy.

Prell RA, Halpern WG, Rao GK.

Int J Toxicol. 2016 May;35(3):263-73. doi: 10.1177/1091581815625596. Epub 2016 Jan 18.

PMID:
26786669
7.

Cytokine release assays: current practices and future directions.

Finco D, Grimaldi C, Fort M, Walker M, Kiessling A, Wolf B, Salcedo T, Faggioni R, Schneider A, Ibraghimov A, Scesney S, Serna D, Prell R, Stebbings R, Narayanan PK.

Cytokine. 2014 Apr;66(2):143-55. doi: 10.1016/j.cyto.2013.12.009. Epub 2014 Jan 10. Review.

PMID:
24412476
8.

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.

Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G, Eigenbrot C.

Cancer Cell. 2011 Oct 18;20(4):472-86. doi: 10.1016/j.ccr.2011.09.003.

9.

Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease.

Bahjat KS, Prell RA, Allen HE, Liu W, Lemmens EE, Leong ML, Portnoy DA, Dubensky TW Jr, Brockstedt DG, Giedlin MA.

J Immunol. 2007 Dec 1;179(11):7376-84.

10.

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.

Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K.

Clin Cancer Res. 2006 Nov 15;12(22):6808-16.

11.

Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma.

Chu Y, Wang LX, Yang G, Ross HJ, Urba WJ, Prell R, Jooss K, Xiong S, Hu HM.

J Immunother. 2006 Jul-Aug;29(4):367-80.

PMID:
16799332
12.

The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration.

Prell RA, Gearin L, Simmons A, Vanroey M, Jooss K.

Cancer Immunol Immunother. 2006 Oct;55(10):1285-93. Epub 2006 Jan 12.

PMID:
16408214
13.
14.

The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement.

Weinberg AD, Evans DE, Thalhofer C, Shi T, Prell RA.

J Leukoc Biol. 2004 Jun;75(6):962-72. Epub 2004 Mar 2. Review.

PMID:
14996827
15.

OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent.

Prell RA, Evans DE, Thalhofer C, Shi T, Funatake C, Weinberg AD.

J Immunol. 2003 Dec 1;171(11):5997-6005.

16.
17.

CTL hyporesponsiveness induced by 2,3,7, 8-tetrachlorodibenzo-p-dioxin: role of cytokines and apoptosis.

Prell RA, Dearstyne E, Steppan LG, Vella AT, Kerkvliet NI.

Toxicol Appl Pharmacol. 2000 Aug 1;166(3):214-21.

PMID:
10906285
18.

Engagement of the OX-40 receptor in vivo enhances antitumor immunity.

Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, Urba WJ, Alvord G, Bunce C, Shields J.

J Immunol. 2000 Feb 15;164(4):2160-9.

19.

Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion.

Maxwell JR, Weinberg A, Prell RA, Vella AT.

J Immunol. 2000 Jan 1;164(1):107-12.

21.

[Successful pressure decrease and improved patient quality of life by Trusopt].

Prell R.

Klin Monbl Augenheilkd. 1996 Apr;208(4):11-2. German. No abstract available.

PMID:
8778487
22.

Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on anti-CD3-induced changes in T-cell subsets and cytokine production.

Prell RA, Oughton JA, Kerkvliet NI.

Int J Immunopharmacol. 1995 Nov;17(11):951-61.

PMID:
8788124

Supplemental Content

Support Center